Some say a new treatment for the bone-weakening disease is a breakthrough. May 2, 2007 — -- A new option in the treatment of osteoporosis could one day change the way many of the 10 million ...

Zoledronic acid 5 mg/100 mL bottle; solution for IV infusion. Paget’s disease of bone is characterized by greatly increased and disorderly bone remodeling. Excessive osteoclastic bone resorption is ...

Reclast (zoledronic acid) is a medication that the Food and Drug Administration (FDA) has approved for preventing and treating osteoporosis in females after menopause, males, and individuals who take ...

The U.S. Food and Drug Administration (FDA) has approved Reclast® (zoledronic acid) Injection, the first and only once-yearly treatment for postmenopausal osteoporosis. Approximately 8 million women ...

Medicare covers the injectable drug, Reclast, when a doctor deems it medically necessary for the treatment and prevention of osteoporosis. There are specific eligibility criteria, including having ...

(1) Reclast provides year-long bisphosphonate compliance with a single infusion. Reclast is the only yearly treatment approved to reduce the risk of fractures in areas of the body typically affected ...

ZURICH, June 5 (Reuters) - U.S. regulators have broadened approval for use of Novartis AG's osteoporosis drug Reclast for prevention of new fractures in patients who have recently had a low-trauma ...

One major warning sign of osteoporosis is a “fragility fracture”—a broken bone caused by something minor like a simple fall.

Please provide your email address to receive an email when new articles are posted on . An annual infusion of zoledronic acid was associated with less bone loss in adults with acute spinal cord injury ...

Please provide your email address to receive an email when new articles are posted on . A single dose of zoledronic acid effectively maintains large and rapid gains in spine and hip bone mineral ...